New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 1, 2023 - Sanofi announced that Adlyxin (lixisenatide) will no longer be available in the U.S. market.
Download PDF
Return to publications
